News
How RFK Jr.'s cuts to mRNA vaccine funding could hurt public health
Health Secretary Robert F. Kennedy Jr. is cutting nearly $500 million in funding for the development of mRNA vaccines that are used to fight COVID-19 and the flu. Dr. Paul Offit joins us to discuss what the move could mean for vaccine research and development.
Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...
CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...
Moderna, Inc.'s Q2 2025 earnings highlight a steep revenue decline post-pandemic, with just $0.1bn in revenue and a $(0.8bn) ...
CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...
In a note to employees on Thursday, Moderna Inc. said it was laying off about 10% of its global workforce as part of the ...
Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...
The layoffs are part of an ongoing effort to reduce operating costs amid government and competitive challenges to its vaccine ...
Moderna said on Thursday it would trim roughly 10% of its global workforce and have fewer than 5,000 employees by the end of ...
Massachusetts-based Moderna, one of the companies at the forefront of developing a vaccine during the COVID pandemic, ...
Moderna CEO Stephane Bancel said in a memo to employees that the company expects to reduce its workforce to fewer than 5,000 ...
Moderna trimmed its 2025 revenue forecast on Friday after UK deliveries of some COVID vaccines were deferred to next year, ...
Barchart on MSN12h
Moderna Stock: Is Wall Street Bullish or Bearish?
With a market cap of $10.7 billion, Moderna, Inc. (MRNA) is a biotechnology company specializing in the development of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback